Ankit Watts
Overview
Explore the profile of Ankit Watts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
76
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaur H, Kumar S, Watts A, Singh C, Sachdeva M, Sreedharanunni S, et al.
Clin Nucl Med
. 2025 Mar;
PMID: 40051087
Purpose: 68Ga-Pentixafor PET/CT targets CXCR4 receptors and provides superior diagnostic accuracy in multiple myeloma (MM) compared with 18F-FDG PET/CT. However, its role in response evaluation remains unexplored. We propose a...
2.
Waheed A, Singh B, Watts A, Kaur H, Singh H, Dhingra K, et al.
Clin Nucl Med
. 2024 Feb;
49(4):e141-e148.
PMID: 38350065
Purpose: The aim of this study was to evaluate the diagnostic potential of 68 Ga-pentixafor PET/CT for in vivo CXCR4 receptors imaging in glioma and its possible role in response...
3.
Jena S, Watts A, Aggarwal P, Bachhal V, Kaur H, Dhingra K, et al.
Nucl Med Commun
. 2024 Jan;
45(3):229-235.
PMID: 38165171
Objective: To evaluate the diagnostic utility of 68 Ga-Pentixafor PET/CT for in vivo imaging of CXCR4 receptors in soft tissue/bone sarcoma. Methods: Ten (7M: 3F; mean age = 24.7 ± ...
4.
Singh B, Sahani G, Prasad V, Watts A, Kumar R
Indian J Nucl Med
. 2023 Dec;
38(3):201-207.
PMID: 38046962
No abstract available.
5.
Kumar R, Singh B, Singh H, Watts A, Kamaldeep
Indian J Nucl Med
. 2023 Feb;
37(Suppl 1):S13-S14.
PMID: 36843639
No abstract available.
6.
Watts A, Singh B, Singh H, Bal A, Kaur H, Dhanota N, et al.
Eur J Nucl Med Mol Imaging
. 2022 Dec;
50(4):1216-1227.
PMID: 36482077
Purpose: In vivo CXCR4 receptor quantification in different lung cancer (LC) sub-types using [Ga]Ga-Pentixafor PET/CT and to study correlation with quantitative CXCR4 receptors' tissue density by immunochemistry analyses. Methods: [Ga]Ga-Pentixafor...
7.
Kumar A, Jacob P, Watts A, Joseph A, Kaur H, Hooda M, et al.
Indian J Nucl Med
. 2022 Aug;
37(2):113-120.
PMID: 35982821
Objectives: The objective is to standardize the reconstruction parameters for the time-of-flight (TOF) non-TOF positron-emission tomography/computed tomography (PET/CT) imaging data and validation of the same in a clinical setting. Methods:...
8.
Sharma P, Watts A, Singh H
Clin Nucl Med
. 2022 Aug;
47(11):948-953.
PMID: 35961365
Background: Prostate cancer (PCa) is the most common cancer in men worldwide. Targeting prostate-specific membrane antigen (PSMA) using radiopharmaceuticals has shown promising results for PCa imaging as well as theranostics....
9.
Shekhawat A, Singh B, Malhotra P, Watts A, Basher R, Kaur H, et al.
Br J Radiol
. 2022 Jun;
95(1136):20211272.
PMID: 35731811
Objectives: Ga-Pentixafor positron emission tomography (PET) imaging targets CXCR4 expression which is overexpressed in multiple myeloma (MM). In this study, we evaluated the diagnostic utility of Ga-Pentixafor PET/CT for imaging...
10.
Watts A, Singh B, Singh H, Kaur H, Bal A, Vohra M, et al.
J Nucl Med Technol
. 2022 May;
50(3):278-281.
PMID: 35610039
Ga-pentixafor PET/CT imaging allows noninvasive assessment of C-X-C chemokine receptor type 4 (CXCR4) expression in various malignancies, but its use in rare lung cancer variants has not been reported. Ga-pentixafor...